Evidence map›Paper›PMID 38935769›Full record

ArticleAnnals of the American Thoracic Society2024

The Hidden Epidemic of Isoniazid-Resistant Tuberculosis in South Africa.

Marisa Klopper, Charnay J van der Merwe, Yuri F van der Heijden, Megan Folkerts, Johannes Loubser, Elizabeth M Streicher, Kate Mekler, Cindy Hayes, David M Engelthaler, John Z Metcalfe and 1 more

Abstract read
In one paragraph

Article in Annals of the American Thoracic Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Marisa KlopperDivision of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0002-9318-8289
Charnay J van der MerweDivision of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0002-5349-0715
Yuri F van der HeijdenDivision of Infectious Diseases, Department of Medicine, School of Medicine, Vanderbilt University, Nashville, Tennessee.ORCID 0000-0001-7631-9796
Megan FolkertsPathogen and Microbiome Division, Translational Genomics Research Institute, Flagstaff, Arizona.ORCID 0000-0001-7430-1701
Johannes LoubserDivision of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0002-2362-0187
Elizabeth M StreicherDivision of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0003-3901-1981
Kate MeklerBeyond Zero, Port Elizabeth, South Africa.
Cindy HayesNational Health Laboratory Services, Port Elizabeth, South Africa; and.
David M EngelthalerPathogen and Microbiome Division, Translational Genomics Research Institute, Flagstaff, Arizona.ORCID 0000-0001-5945-059X
John Z MetcalfeDivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital and Trauma Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-2279-7036
Robin M WarrenDivision of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0001-5741-7358

Funding

Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infectionR01AI131939 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ENGELTHALER, DAVID M, METCALFE, JOHN ZAPATA · 2018 to 2023
$3.9M
Fluoroquinolone resistance in patients with multidrug-resistant tuberculosisK08AI106420 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI VAN DER HEIJDEN, YURI F. · 2014 to 2018
$848k
Development of a Next-generation Rapid Phenotypic Assay for Drug-Resistant M. tuberculosisK43TW012591 · FIC · STELLENBOSCH UNIVERSITY · PI Marisa Klopper · 2023 to 2026
$424k
EDCTP2 programme supported by the European Union TMA2017CDF-1885FIC NIH HHS K43 TW012591National Institute of Allergy and Infectious Diseases R01AI131939NIAID NIH HHS K08 AI106420NIAID NIH HHS R01 AI131939NIH HHS K08AI106420NIH HHS K43TW012591South African Medical Research CouncilStellenbosch University Ukwanda Fund for Innovation and Research in Rural Health
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antitubercular AgentsIsoniazidMicrobial Sensitivity TestsMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAdultBacterial ProteinsCatalaseEpidemicsFemaleGenotypeHumansMaleMiddle AgedMutationOxidoreductasesAntitubercular AgentsBacterial ProteinsCatalaseInhA protein, MycobacteriumIsoniazidkatG protein, Mycobacterium tuberculosisOxidoreductasesRifampinisoniazid mono resistancemechanisms of resistancenext generation sequencingtuberculosis epidemiology

Identifiers

PMID38935769
PMCPMC11451881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.